Retrospective Analysis for Patients With Metabolic Syndrome

Recruiting

• Conditions: Metabolic Syndrome
• Interventions: Other: dietary, semaglutide or/and metformin

• Registration Number: NCT06182618
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-01
• Status Verified: 2023-11
• Study First Submitted: 2023-11-30
• Study First Submitted QC: 2023-12-24
• Last Update Submitted: 2023-12-24
• Study First Posted: 2023-12-27
• Last Update Posted: 2023-12-27
• Primary Completion: 2024-01-01
• Study Completion: 2024-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.

Exclusion Criteria

• patients did not follow-up on a monthly basis;
• patients followed-up less than 1 times within 3 months;
• patients having incomplete data;
• patients changing their interventions during fol-low-ups

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
balanced diet	dietary, semaglutide or/and metformin	50-65% carbohydrate, 20-30% fat and 10-20% protein
low-carbohydrate diet	dietary, semaglutide or/and metformin	20-30% carbohydrates, 40-45%fat, and 30-40%protein
pharmacotherapy	dietary, semaglutide or/and metformin	semaglutide (1mg per week) or/and metformin (o.5g three times a day)

Primary Outcome Measures

Name	Time	Method
weight	0month/1month/2months/3 months	Weight was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points

Secondary Outcome Measures

Name	Time	Method
visceral fat area(VFA)	0month/1month/2months/3 months	VFA was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points
skeletal muscle mass(SMM)	0month/1month/2months/3 months	SMM was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points

Trial Locations

Locations (1)

The Second Affiliated Hospital, College of Medicine, Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China